Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel
Launched by FUNDACIÓN INSTITUTO VALENCIANO DE ONCOLOGÍA · Jan 5, 2016
Trial Information
Current as of June 19, 2025
Unknown status
Keywords
ClinConnect Summary
Intraindividual comparative study, to evaluate efficacy and safety of the treatment of actinic keratosis with photodynamic therapy between methyl aminolevulinate cream (MAL) and aminolevulinic acid nanosoma gel (ALA).
MAL cream: is an antineoplastic agent used as a photosensitizer for photodynamic therapy (PDT). The mode of action of methyl aminolevulinate in PDT was shown in the pharmacodynamic (PD) studies. In the target cells,methyl aminolevulinate was converted to photoactive porphyrins, including protoporphyrinIX (PpIX), which are the active photosensitizers. Upon light activation, th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1 Patient over 18 years old and capable of giving informed consent.
- • 2. Provide at least 5 QA in two symmetrical areas of the face or scalp.
- • 3. Accept the abandonment of sun creams and other creams (retinoic hydroxy acids, emollients, Topical Antibiotics ) in the treatment area during the time of the study.
- • 4. Accept that it will postpone the treatment of other actinic keratosis close to treatment area.
- • 5. Accept to go to scheduled visits. They should answer a questionnaire about epidemiology, history and treatment satisfaction. They will accept a photo of treatment area at each visit.
- Exclusion Criteria:
- • 1. Have any dermatological disease on the treatment zone or around it.
- • 2. Patients who have previously been treated with therapy Photodynamic in targeted areas.
- • 3. Patients with alcohol or drug dependence.
- • 4. Patients who are currently participating in other studies.
- 5. Patients who have received any of the following medications at a time less than the indicated:
- • Systemic chemotherapy in the last 6 months.
- • Retinoids systemic , interferon , immunomodulatory or immunosuppressive , cytotoxic including agents , corticosteroids systemic , in the last month .
- • Ultraviolet A light, Ultraviolet B light, ablative laser, dermabrasion, chemical peels, in the last 6 months.
- • Topical retinoids , topical 5 -fluorouracil in the last month.
- • Cryotherapy , surgical excision, curettage, topical corticosteroids in the last month.
About Fundación Instituto Valenciano De Oncología
The Fundación Instituto Valenciano de Oncología (FIVO) is a leading research institution dedicated to advancing cancer care and treatment through innovative clinical trials and comprehensive oncology research. Based in Valencia, Spain, FIVO is committed to improving patient outcomes by integrating cutting-edge scientific discoveries with clinical practice. The foundation collaborates with a network of healthcare professionals and research organizations to develop and evaluate novel therapeutic approaches, focusing on personalized medicine and the latest advancements in oncology. FIVO's mission is to enhance the understanding of cancer biology and translate this knowledge into effective interventions that benefit patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Trial Officials
Carlos Serra
Principal Investigator
Servicio Dermatologia FIVO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials